All questionsIndication: Kesimpta (ofatumumab) in relapsing multiple sclerosis5 questions · 2 sourcesIndicationWhat is Kesimpta approved for?“KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.” (opens the source at this quote in a new tab)CopyFlagDrug namesWhat is the generic name of Kesimpta?“KESIMPTA® (ofatumumab) injection, for subcutaneous use” (opens the source at this quote in a new tab)CopyFlag“KESIMPTA (ofatumumab) injection is a sterile, preservative-free solution for subcutaneous use.” (opens the source at this quote in a new tab)CopyFlagWhat type of drug is Kesimpta (drug class)?“KESIMPTA is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. (1)” (opens the source at this quote in a new tab)CopyFlag“Ofatumumab is a recombinant human monoclonal immunoglobulin G1 (IgG1) antibody that binds to human CD20 expressed on B-cells. Ofatumumab is produced in a murine NS0 cell line and consists of two IgG1 heavy chains and two kappa light chains with a molecular weight of approximately 146 kDa.” (opens the source at this quote in a new tab)CopyFlagTestingWhat tests are needed before starting Kesimpta?“Before initiating KESIMPTA, screen for Hepatitis B virus (HBV) and obtain serum quantitative immunoglobulins, aminotransferases, alkaline phosphatase, and bilirubin. (2.1)” (opens the source at this quote in a new tab)CopyFlag“Screen your patients for HBV, monitor Ig levels, and obtain liver function tests1 Hint: HBV, Ig, and liver function testing can be added to your patient’s regular blood panels” (opens the source at this quote in a new tab)CopyFlagHow should patients be screened for hepatitis B before Kesimpta?“HBV screening should be performed in all patients before initiation of treatment with KESIMPTA. At a minimum, screening should include Hepatitis B surface antigen (HBsAg) and Hepatitis B Core Antibody (HBcAb) testing. These can be complemented with other appropriate markers as per local guidelines. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment with KESIMPTA. These patients should be monitored and managed following local medical standards to prevent HBV infection or reactivation.” (opens the source at this quote in a new tab)CopyFlag